SXTP

Company Overview — What Does 60 DEGREES PHARMACEUTICALS, INC. Do?

We are a growth-oriented specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda, a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for COVID-19, fungal, tick-borne, and other viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir. Our mission is to address the unmet medical need associated with infectious diseases, through the development and commercialization of new small molecule therapeutics, focusing on synthetic drugs (made by chemists in labs, excluding biologics) with good safety profiles based on prior clinical studies, in order to reduce cost, risk, and capitalize on existing research. We are seeking to expand Arakoda’s use for malaria prevention and to demonstrate clinical benefit for other disease indications. We are further testing the viability of another product (Celgosivir) to determine whether to advance it into further clinical development, and may seek to develop and license other molecules in the future. Celgosivir is being developed for COVID-19, RSV and Dengue. Our principal executive offices are located at 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 60 DEGREES PHARMACEUTICALS, INC. (SXTP) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Geoffrey Dow. With a market capitalization of $5M, SXTP is one of the notable companies in the Healthcare sector.

60 DEGREES PHARMACEUTICALS, INC. (SXTP) Stock Rating — Reduce (April 2026)

As of April 2026, 60 DEGREES PHARMACEUTICALS, INC. receives a Reduce rating with a composite score of 32.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.SXTP ranks #3,685 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, 60 DEGREES PHARMACEUTICALS, INC. ranks #605 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

SXTP Stock Price and 52-Week Range

60 DEGREES PHARMACEUTICALS, INC. (SXTP) currently trades at $1.46. The stock lost $0.28 (16.1%) in the most recent trading session. The 52-week high for SXTP is $8.62, which means the stock is currently trading -83.1% from its annual peak. The 52-week low is $0.34, putting the stock 329.5% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.

Is SXTP Overvalued or Undervalued? — Valuation Analysis

60 DEGREES PHARMACEUTICALS, INC. (SXTP) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.38x, versus the sector average of 2.75x. The price-to-sales ratio is 4.47x, compared to 1.66x for the average Healthcare stock.

At current multiples, 60 DEGREES PHARMACEUTICALS, INC. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

60 DEGREES PHARMACEUTICALS, INC. Profitability — ROE, Margins, and Quality Score

60 DEGREES PHARMACEUTICALS, INC. (SXTP) earns a quality factor score of 25/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -239.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -150.8% versus the sector average of -33.1%.

On a margin basis, 60 DEGREES PHARMACEUTICALS, INC. reports gross margins of 16.6%, compared to 71.5% for the sector. The operating margin is -946.8% (sector: -66.1%). Net profit margin stands at -959.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 250.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

SXTP Debt, Balance Sheet, and Financial Health

60 DEGREES PHARMACEUTICALS, INC. has a debt-to-equity ratio of 4.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 2.66x, indicating strong short-term liquidity. Total debt on the balance sheet is $150,000. Cash and equivalents stand at $4M.

SXTP has a beta of -1.32, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for 60 DEGREES PHARMACEUTICALS, INC. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

60 DEGREES PHARMACEUTICALS, INC. Revenue and Earnings History — Quarterly Trend

In TTM 2026, 60 DEGREES PHARMACEUTICALS, INC. reported revenue of $1M and earnings per share (EPS) of $-11.73. Net income for the quarter was $-8M. Gross margin was 16.6%. Operating income came in at $-8M.

In FY 2025, 60 DEGREES PHARMACEUTICALS, INC. reported revenue of $1M and earnings per share (EPS) of $-11.73. Net income for the quarter was $-7M. Gross margin was 22.3%. Revenue grew 65.5% year-over-year compared to FY 2024. Operating income came in at $-8M.

In Q3 2025, 60 DEGREES PHARMACEUTICALS, INC. reported revenue of $437,602 and earnings per share (EPS) of $-0.66. Net income for the quarter was $-2M. Gross margin was -22.9%. Revenue grew 223.4% year-over-year compared to Q3 2024. Operating income came in at $-2M.

In Q2 2025, 60 DEGREES PHARMACEUTICALS, INC. reported revenue of $307,871 and earnings per share (EPS) of $-1.25. Net income for the quarter was $-2M. Gross margin was 16.5%. Revenue grew 146.4% year-over-year compared to Q2 2024. Operating income came in at $-2M.

Over the past 8 quarters, 60 DEGREES PHARMACEUTICALS, INC. has demonstrated a growth trajectory, with revenue expanding from $124,972 to $1M. Investors analyzing SXTP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

SXTP Dividend Yield and Income Analysis

60 DEGREES PHARMACEUTICALS, INC. (SXTP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

SXTP Momentum and Technical Analysis Profile

60 DEGREES PHARMACEUTICALS, INC. (SXTP) has a momentum factor score of 66/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 23/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

SXTP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, 60 DEGREES PHARMACEUTICALS, INC. (SXTP) ranks #605 out of 838 stocks based on the Blank Capital composite score. This places SXTP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing SXTP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full SXTP vs S&P 500 (SPY) comparison to assess how 60 DEGREES PHARMACEUTICALS, INC. stacks up against the broader market across all factor dimensions.

SXTP Next Earnings Date

No upcoming earnings date has been announced for 60 DEGREES PHARMACEUTICALS, INC. (SXTP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy SXTP? — Investment Thesis Summary

The quantitative profile for 60 DEGREES PHARMACEUTICALS, INC. suggests caution. The quality score of 25/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Price momentum is positive at 66/100, suggesting the trend favors buyers. High volatility (stability score 30/100) increases portfolio risk.

In summary, 60 DEGREES PHARMACEUTICALS, INC. (SXTP) earns a Reduce rating with a composite score of 32.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on SXTP stock.

Related Resources for SXTP Investors

Explore more research and tools: SXTP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare SXTP head-to-head with peers: SXTP vs AZN, SXTP vs SLGL, SXTP vs VMD.